Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans

Author's Avatar
Dec 19, 2022

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its President and Chief Executive Officer, Lloyd M. Segal, Executive Vice President and Chief Financial Officer, Steve Forte, Executive Vice President and Chief Medical Officer, Maria Koehler, Executive Vice President and Chief Scientific Officer, Michael Zinda, Executive Vice President and Chief Business Officer, Kim Seth, Executive Vice President, Head of Discovery, Cameron Black, and Executive Vice President Commercial and New Product Development, Philip Herman (collectively, the “Executives”), have established new Automatic Securities Disposition Plans (“ASDPs”), or in the case of Maria Koehler modified her existing ASDP, in accordance with applicable United States and Canadian securities legislation, including U.S. Securities and Exchange Commission (“SEC”) Rule 10b5-1 and the recommended practices set forth in the Canadian Securities Administrators’ Staff Notice 55-317 (“Staff Notice 55-317”) and the Company’s internal policies.